Century Therapeutics (IPSC) Total Current Liabilities (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Total Current Liabilities data on file, last reported at $13.6 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 6.46% year-over-year to $13.6 million in Q1 2026; TTM through Mar 2026 was $13.6 million, a 6.46% decrease from a year earlier, with the FY2025 full-year figure at $20.2 million, down 84.42% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $13.6 million, down from $20.2 million in the prior quarter.
• Over the last five years, Total Current Liabilities for IPSC reached as high as $129.8 million in Q4 2024 and fell as low as $13.6 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $26.8 million across 5 years, with a median of $20.2 million in 2025.
• Across the five-year window, Total Current Liabilities jumped 627.23% in 2024 and sank 84.42% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $29.8 million in 2022, then slumped by 40.15% to $17.8 million in 2023, then soared by 627.23% to $129.8 million in 2024, then sank by 84.42% to $20.2 million in 2025, then sank by 32.93% to $13.6 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $13.6 million in Q1 2026, $20.2 million in Q4 2025, and $22.0 million in Q3 2025.